🇺🇸 FDA
Patent

US 12377093

Pyruvate kinase activators for use in therapy

granted A61KA61K31/415A61K31/4406

Quick answer

US patent 12377093 (Pyruvate kinase activators for use in therapy) held by Agios Pharmaceuticals, Inc. expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Agios Pharmaceuticals, Inc.
Grant date
Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/415, A61K31/4406, A61K31/47, A61K31/496